title: Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care.
abstract: BACKGROUND
  Major depression is a prevalent mental disorder with a high risk of relapses and recurrences, which are associated with considerable burden for patients and high costs for society. Despite these negative consequences, only few studies have focused on interventions aimed at the prevention of recurrences in primary care patients with depression.
  
  
  OBJECTIVE
  To assess the cost-effectiveness of a psychoeducational prevention program (PEP) aimed at improving the long-term outcome of depression in primary care.
  
  
  METHODS
  Recruitment took place in the northern part of the Netherlands, patients were referred by general practitioners. In total 267 patients were included in the study and randomly assigned to usual care (UC) or UC with one of three forms of PEP; PEP alone, psychiatric consultation followed by PEP (psychiatrist-enhanced PEP), and cognitive behavioral therapy followed by PEP (CBT-enhanced PEP). Costs and health outcomes were registered at three month intervals during the 36 months follow-up of the study. Primary outcome measure was the proportion of depression-free time.
  
  
  RESULTS
  Mean total costs during the 36 months of the study were 8200 euros in the UC group, 9816 euros in the PEP group, 9844 euros in the psychiatrist-enhanced PEP group, and 9254 euros in the CBT-enhanced PEP group. Costs of productivity losses, hospital admissions, contacts with regional institutions for mental healthcare, and medication use contributed substantially to the total costs in each group. Results of the primary outcome measure were less positive for PEP than for UC, but slightly better in the enhanced PEP groups. If decision-makers are willing to pay up to 300 euros for an additional proportion of depression-free time, UC is most likely to be the optimal intervention. For higher willingness to pay, CBT-enhanced PEP seems most efficient.
  
  
  CONCLUSIONS
  The basic PEP intervention was not cost-effective in comparison with UC. The economic impact of productivity losses associated with depression, and the importance of including these costs in economic studies, was illustrated by the findings of this study. Due to the drop-out of patients during the 36 months follow-up period, economic analyses had to account for missing data, which may complicate the interpretation of the results. Although Quality-Adjusted Life Years (QALYs) could not be assessed for all the patients, the results of analyses focusing on QALYs supported the overall conclusion that PEP is not cost-effective. IMPLICATIONS FOR HEALTH CARE PROVISION AND POLICIES: Results indicated that PEP should not be implemented in the Dutch healthcare system. Furthermore, is seems highly unlikely that PEP could be cost-effective in other (comparable) European healthcare systems.
  
  
  CONCLUSIONS
  The relatively positive economic results for CBT-enhanced PEP imply that UC enriched with CBT (but without PEP) might be cost-effective in preventing relapses in primary care patients with depression. The actual consequences of CBT for relapse prevention will have to be studied in further detail, both from a clinical and economic point of view.
authors.affiliation: University Medical Center Groningen, Department of Epidemiology, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands, a.d.stant@epi.umcg.nl
authors.forename: A Dennis
authors.initials: AD
authors.lastname: Stant
authors.forename: Elisabeth M
authors.initials: EM
authors.lastname: TenVergert
authors.forename: Herman
authors.initials: H
authors.lastname: Kluiter
authors.forename: Henk Jan
authors.initials: HJ
authors.lastname: Conradi
authors.forename: Annet
authors.initials: A
authors.lastname: Smit
authors.forename: Johan
authors.initials: J
authors.lastname: Ormel
mesh_terms: D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003865:Major Depressive Disorder / Q000191:economics* / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D010353:Patient Education as Topic / Q000191:economics* / Q000379:methods; D011320:Primary Health Care / Q000191:economics*; D011570:Psychiatry / Q000191:economics*; D019057:Quality-Adjusted Life Years; D012008:Recurrence; D012648:Self Care; D020377:Self Efficacy
chemical_list: D000928:Antidepressive Agents